- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Selecting Among Third-Line Therapies in Clinical Practice for mCRC
Panelists discuss how efficacy, safety, quality of life, and patient-specific factors drive selection among third-line therapies in metastatic colorectal cancer.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
EP: 11.Improving Care for mCRC: Overcoming Barriers and Building Confidence in Community Practice
EP: 12.Enhancing Support and Care Coordination in mCRC
Panelists emphasize the complexity of choosing among available third-line therapies, noting that no single option fits all patients. Clinical decision-making weighs efficacy, safety, quality of life, and individual disease characteristics such as molecular profile and comorbidities.
They describe how some patients may be better candidates for trifluridine/tipiracil (FTD/TPI) earlier in the sequence due to tolerability whereas others may benefit more from fruquintinib or regorafenib based on clinical presentation or prior treatment exposures.
The discussion highlights that personalization remains essential, with therapy choice influenced not only by trial data but also by patient-specific goals and real-world circumstances.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
